Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 5.75% on January 5, with a trading volume of 1.625 billion yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of December 31, 2025, the fund's shares stood at 10.492 billion, with a total size of 7.896 billion yuan, indicating no change in shares or size year-to-date [1] Group 2 - The ETF's recent trading activity shows a cumulative trading amount of 16.006 billion yuan over the last 20 trading days, with an average daily trading amount of 800 million yuan [1] - The current fund manager, Ma Jun, has managed the fund since its inception, achieving a return of 50.52% during the management period [1] - The ETF's top holdings include companies such as BeiGene, CanSino Biologics, and Innovent Biologics, with significant weightings in the portfolio [2]
港股创新药ETF（159567）涨5.75%，成交额16.25亿元
Xin Lang Cai Jing·2026-01-06 00:45